NDA 213736 · Incyte Corp
Pemazyre
Pemigatinib · Oral · Kinase Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Aug 26, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Apr 17, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
51
1 Phase 3, 13 recruiting
FAERS reports
853
532 serious, 150 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 9, 2026.
PEMAZYRE is a kinase inhibitor indicated: for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. ( 1 , 2.1 ) This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 , 2.1 ) For the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. ( 1 , 2.1 ) 1.1 Cholangiocarcinoma PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test [see Dosage and Administration ( 2.1 )] . This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14.1 )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement PEMAZYRE is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.
Mechanism: Pemigatinib is a small molecule kinase inhibitor that targets FGFR1, 2 and 3 with IC 50 values of less than 2 nM. Pemigatinib also inhibited FGFR4 in vitro at a concentration approximately 100 times higher than those that inhibit FGFR1, 2, and 3. Pemigatinib inhibited FGFR1-3 phosphorylation and signaling and decreased cell viability in cancer cell lines with activating FGFR amplifications and fusions that resulted in constitutive activation of FGFR signaling. Constitutive FGFR signaling can support the proliferation and survival of malignant cells. Pemigatinib exhibited anti-tumor activity...
Therapeutic areas: Oncology · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 26, 2022 Supplement 2 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Apr 17, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
3 products under this application
- PEMAZYRE · PEMIGATINIB 13.5MG · TABLET, ORAL · Prescription
- PEMAZYRE · PEMIGATINIB 4.5MG · TABLET, ORAL · Prescription
- PEMAZYRE · PEMIGATINIB 9MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pemigatinib" as an intervention, any sponsor and status, largest first.
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- Molecularly Tailored Therapy in Advanced Pancreatic CancerPivotal-lookingNot yet recruiting
Herlev HospitalAcademic, hospital or other
NCT07802418 · 1,200 participants (planned) · Start Oct 2026 · Primary completion Jun 2031
Drug: Arm 1: Molecularly Tailored Therapy; Arms 2: Standard-of-Care Therapy and 1 more · For: Pancreatic Cancer
Sites: Aalborg, Denmark; Aarhus, Denmark; Herlev, Denmark · 4 sites in all
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SitePivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03498521 · 529 participants · Start Jul 10, 2018 · Primary completion Feb 14, 2023
Drug: Alectinib; Vismodegib and 16 more · For: Cancer of Unknown Primary Site
Sites: Blacktown, Australia; St Leonards, Australia; South Brisbane, Australia · 125 sites in all
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyPivotal-lookingStatus unknown
Fondazione per la Medicina PersonalizzataAcademic, hospital or other
NCT04591431 · 400 participants · Start Oct 7, 2020 · Primary completion Dec 2024
Drug: Erlotinib; Trastuzumab and 24 more · For: Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer and 1 more
Sites: Ancona, Italy; Aviano, Italy; Bari, Italy · 37 sites in all
- A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)Pivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT02872714 · 263 participants · Start Jan 12, 2017 · Primary completion Feb 1, 2022
Drug: pemigatinib; pemigatinib · For: UC (Urothelial Cancer)
Sites: Tucson, Arizona; San Diego, California; San Francisco, California · 96 sites in all
Helsinki University Central HospitalAcademic, hospital or other
NCT05159245 · 250 participants (planned) · Start Dec 10, 2021 · Primary completion Nov 25, 2031
Drug: Alectinib; Cobimetinib and 13 more · For: Advanced Cancer; Solid Tumor; Haematological Malignancy
Sites: Turku, Finland; Helsinki, Finland; Kuopio, Finland · 5 sites in all
Incyte CorporationIncyte (INCY)
NCT04463771 · 206 participants · Start Jan 26, 2021 · Primary completion May 29, 2026
Drug: retifanlimab; epacadostat and 3 more · For: Endometrial Cancer
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 65 sites in all
Incyte CorporationIncyte (INCY)
NCT02393248 · 201 participants · Start Feb 27, 2015 · Primary completion Dec 17, 2021
Drug: Pemigatinib; Gemcitabine and 5 more · For: Lung Cancer; Solid Tumor; Gastric Cancer and 8 more
Sites: Birmingham, Alabama; West Hollywood, California; New Haven, Connecticut · 20 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use155
- disease progression144
- death86
- fatigue82
- alopecia67
- cholangiocarcinoma62
- hyperphosphataemia54
- drug ineffective48
- diarrhoea46
- nausea43
- constipation40
- hospitalisation40
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 101 |
| 2021 | 89 |
| 2022 | 66 |
| 2023 | 279 |
| 2024 | 123 |
| 2025 | 95 |
| 2026 | 100 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pemazyre (Pemigatinib)
2024 spending
$29.5M
Beneficiaries
221
1,481 claims
Per beneficiary
$133,629
$1,327.70 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,305,282 |
| 2021 | $19,119,498 |
| 2022 | $25,659,299 |
| 2023 | $26,255,018 |
| 2024 | $29,532,057 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Abou-Alfa GK, Sahai V, Hollebecque A, et al. · Lancet Oncol 2020 · Clinical Trial, Phase II, Multicenter Study
- Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.
Verstovsek S, Kiladjian JJ, Vannucchi AM, et al. · NEJM Evid 2025 · Clinical Trial, Phase II
- An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.
Vogel A, Sahai V, Hollebecque A, et al. · ESMO Open 2024 · Multicenter Study, Clinical Trial, Phase II
- Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
Rodón J, Damian S, Furqan M, et al. · Nat Med 2024 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V, Iannotti NO, Gutierrez M, et al. · Ann Oncol 2022 · Clinical Trial, Phase I, Clinical Trial, Phase II
- FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.
Bekaii-Saab TS, Valle JW, Van Cutsem E, et al. · Future Oncol 2020 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Incyte
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.